Hannon Rosemary A, Eastell Richard
Academic Unit of Bone Metabolism, Division of Clinical Sciences (North), University of Sheffield Clinical Sciences Centre, Northern General Hospital, Herries Rd, Sheffield S5 7AU, UK.
Cancer Treat Rev. 2006;32 Suppl 1:7-14. doi: 10.1016/s0305-7372(06)80003-4.
Metastasis of cancer to bone leads to significant alterations in normal bone remodelling that are reflected in changes in bone turnover markers. These markers are classically defined as markers of bone resorption or formation; markers of bone resorption are measures of osteoclastic activity, whereas markers of bone formation are measures of osteoblastic activity. Recently, there has been growing interest in the use of these markers in metastatic bone disease (MBD), and an increasing number of studies have investigated the potential use of these markers in diagnosis, monitoring of disease progression and treatment, and prediction of outcome. In this review, we briefly discuss the biology of bone metastases as well as describe the bone turnover markers and their possible role in aiding clinicians in the treatment of patients with MBD.
癌症转移至骨会导致正常骨重塑发生显著改变，这反映在骨转换标志物的变化上。这些标志物传统上被定义为骨吸收或形成的标志物；骨吸收标志物是破骨细胞活性的指标，而骨形成标志物是成骨细胞活性的指标。最近，人们对这些标志物在转移性骨病（MBD）中的应用越来越感兴趣，并且越来越多的研究探讨了这些标志物在诊断、疾病进展监测与治疗以及预后预测方面的潜在用途。在本综述中，我们简要讨论骨转移的生物学特性，并描述骨转换标志物及其在协助临床医生治疗MBD患者方面可能发挥的作用。
